Adenike Tinubu, MD
Family Medicine · Opelousas, LANPI 1306055652
Payments from drug & device makers
Across 197 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$443
- Boehringer Ingelheim$407
- Novartis$306
- Novo Nordisk$242
- Pfizer$210
- plus $708 from 17 others
What the payments were for
- Food & beverage$3,589100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,273 |
| GSK | 32 | $443 |
| Boehringer Ingelheim | 21 | $407 |
| Novartis | 18 | $306 |
| Novo Nordisk | 13 | $242 |
| Pfizer | 17 | $210 |
| Gilead | 5 | $119 |
| AbbVie(2 entities) | 7 | $95 |
| Scilex Pharmaceuticals Inc. | 1 | $73 |
| Lilly USA, LLC | 4 | $65 |
| Bayer | 3 | $58 |
| Amgen | 3 | $56 |
| Verona Pharma, Inc. | 2 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Exact Sciences | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Global Blood Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,589 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 359 | $345,550 |
| JardianceEmpagliflozin | 412 | $260,674 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 306 | $205,140 |
| TradjentaLinagliptin | 194 | $104,850 |
| FarxigaDapagliflozin Propanediol | 156 | $89,902 |
| JanuviaSitagliptin Phosphate | 124 | $86,331 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $68,569 |
| MounjaroTirzepatide | 50 | $51,644 |
| RexultiBrexpiprazole | 38 | $49,685 |
| XareltoRivaroxaban | 76 | $44,910 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,917 | $41,595 |
| EntrestoSacubitril/Valsartan | 60 | $39,816 |
| LinzessLinaclotide | 50 | $27,376 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $23,978 |
| EliquisApixaban | 40 | $22,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $407 | $385,050646 claims |
| Novo NordiskOzempic, Rybelsus | $242 | $367,825384 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $443 | $246,766405 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,273 | $158,471261 claims |
| Lilly USA, LLCMounjaro, Trulicity | $65 | $67,58866 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $19 | $49,68538 claims |
| NovartisEntresto | $306 | $39,81660 claims |
| AbbVieLinzess | $95 | $27,37650 claims |
| PfizerEliquis | $210 | $22,85840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Opelousas
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.